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Background: Superior cavopulmonary anastomosis is widely used for palliation of
various forms of univentricular heart defects. However, clinically significant pul-
monary arteriovenous malformations develop in 15% to 25% of patients after
surgery.
Objective: To assess altered regulation of pulmonary vascular tone caused by supe-
rior cavopulmonary anastomosis in an ovine model.
Methods: Lambs, aged 35 to 45 days, underwent an end-to-end anastomosis of the
superior vena cava to the right pulmonary artery. In age-matched controls, a sham
operation was performed. Arteriovenous malformations were detectable by contrast
echocardiography by 8 weeks after surgery. Animals (n = 24) were studied at vari-
ous time points after the operations. Expression of angiotensin-converting enzyme
messenger RNA, protein levels, and enzyme activity were measured in lung
homogenates. Levels of angiotensin II were measured by enzyme-linked
immunosorbent assay. 
Results: Expression of angiotensin-converting enzyme messenger RNA and protein
was significantly reduced at 1 to 5 weeks after superior cavopulmonary anastomo-
sis. Angiotensin-converting enzyme activity in the right lung of animals subjected
to superior cavopulmonary anastomosis was reduced 86% ± 1% (standard devia-
tion) compared with control values at 1 week (P = .003) and 77% ± 8.5% at 2 weeks
(P < .001) after surgery. This correlated with a 59% ± 3.5% (P = .007) reduction in
angiotensin II levels up to 5 weeks after cavopulmonary anastomosis. By 15 weeks
after the operations, angiotensin II levels were equivalent to control levels (P = .19). 
Conclusions: Superior cavopulmonary anastomosis causes an early reversible
reduction in activity and expression of angiotensin-converting enzyme, resulting in
decreased circulating levels of the vasoconstrictor angiotensin II. These results sug-
gest that the ability of the pulmonary endothelium to regulate vascular tone is inhib-
ited after superior cavopulmonary anastomosis. Dilation of the affected vasculature
induced by cavopulmonary anastomosis may contribute to the disordered vascular
remodeling observed in this setting.
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First applied clinically by Glenn in 1958, superi-or cavopulmonary anastomosis (SCPA), alsoknown as the classic Glenn shunt, is performedfor palliation of tricuspid atresia and univen-tricular congenital heart defects.1 SCPA is anend-to-end anastomosis of the superior vena
cava to the right pulmonary artery with ligation of the cavoa-
trial junction and division of the proximal right pulmonary
artery. Unlike systemic arterial shunts, this procedure increas-
es pulmonary blood flow without increasing the workload of
the ventricle. Unfortunately, pulmonary arteriovenous (AV)
malformations develop in a significant proportion of patients
undergoing SCPA. Several studies have demonstrated AV
malformations in 10% to 60% of patients.2-4 These AV mal-
formations range in clinical significance from asymptomatic
to progressive cyanosis and hypoxemia.
The cause of AV malformation in this setting is unknown.
To study this phenomenon, we have developed an ovine
model that reliably produces pulmonary AV shunting
detectable by bubble contrast echocardiography 6 to 8
weeks after construction of cavopulmonary anastomoses
(submitted for publication). Histologic analysis of the
affected lung reveals the proliferation of thin-walled, dilat-
ed vessels. On gross examination, numerous dilated sub-
pleural vessels are visible on lungs from post-SCPA lambs.
These observations suggested that impaired pulmonary
vasoconstriction may play a role in the development of AV
malformations. We hypothesized that regulation of pul-
monary vascular tone would be disrupted after cavopul-
monary anastomosis, resulting in chronic dilation of the
affected vasculature. Angiotensin-converting enzyme
(ACE) was studied because it is a powerful regulator of vas-
cular tone located predominantly on the pulmonary
endothelial surface. Its importance in pulmonary arterial
vasoconstriction is highlighted by its ability to both gener-
ate the vasoconstrictor angiotensin II (AT-II) and inactivate
the vasodilator bradykinin.
Methods
Surgical Preparation 
Mixed Western lambs (35-45 days old) were anesthetized and their
lungs were mechanically ventilated. After median sternotomy and
pericardiotomy, the superior vena cava and right pulmonary artery
were identified and dissected free from their attachments (Figure
1). Intravenous heparin was administered (300 U/kg) and 16F to
20F venous cannulas were placed to bypass the superior vena cava
to the right atrium. The right pulmonary artery was divided near
the pulmonary bifurcation and the proximal end was oversewn.
The superior vena cava was similarly divided at the cavoatrial
junction and the atrial end was oversewn. The superior vena cava
was then anastomosed to the right pulmonary artery in an end-to-
end fashion with running polypropylene suture. The venous can-
nulas were removed and the sternum closed. After skin closure, the
lambs were extubated and allowed to recover.
A second group of lambs of the same age served as sham-oper-
ated controls. The preparation and dissection were the same as
described for the SCPA cohort. The right pulmonary artery was
occluded with a vascular clamp for 30 minutes. After this time, the
clamp was removed and the chest was closed as described above.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society of Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources and published by the National
Institutes of Health. The protocol was approved by the Committee
on Animal Research at the University of California, San Francisco.
Echocardiography 
Pulmonary AV shunting was demonstrated by bubble contrast
echocardiography. Epicardial echocardiography was performed on
each animal after median sternotomy. Next, 5 mL of a saline solu-
tion/blood mixture was agitated to produce bubbles and then
injected sequentially into the superior and inferior venae cavae.
The presence of bubbles in the left atrium within 5 cardiac cycles
after injection of the superior vena cava indicates pulmonary AV
shunting.4 The absence of bubbles in the right atrium after injec-
tion of the superior vena cava excludes systemic venovenous
shunting. The absence of bubbles returning to the left atrium after
inferior vena caval injection excludes pulmonary AV shunting in
the left lung.
Tissue Harvest 
Lambs were put to death 1, 2, 5, and 15 weeks after surgery to
obtain tissue for analysis. At each time point, 3 SCPA animals and
3 sham controls were put to death for a total of 24 sheep studied.
Animals were intubated and their lungs were mechanically venti-
lated. After median sternotomy, the lambs were anticoagulated
with sodium heparin (300 U/kg). The superior and inferior venae
cavae and the right pulmonary artery and vein were identified and
blood samples were obtained from each vessel. The lambs were
then put to death with an infusion of sodium pentobarbital. The
lungs were removed, perfused with 0.9% NaCl solution, and sam-
ples were snap frozen in liquid nitrogen.
Reverse Transcription–Polymerase Chain Reaction 
Total RNA was prepared from homogenates of right lower lobe
lung tissue from control and SCPA lambs studied at selected time
points after the operations. RNA was extracted with the use of the
TRI reagent RNA isolation protocol (Molecular Research Center,
Inc, Cincinnati, Ohio). Samples were incubated with oligo (dT)
and reverse transcriptase (Superscript Kit; Gibco BRL, Life
Technologies, Inc, Rockville, Md) at 42°C for 50 minutes. The
resulting complementary DNA underwent polymerase chain reac-
tion (PCR) with the use of the following primers: 5´ AGGCTGAT-
GATTTCTTCACCTCC 3´ and 5´ GCGTAGACAGTGA-
GAGGGCTAG 3´. PCR was initiated with 3 minutes of
denaturation at 95°C followed by 25 cycles of 30 seconds of dena-
turation at 95°C, 30 seconds of annealing at 55°C, and 2 minutes
of extension at 72°C, followed by 10 additional minutes of the
extension step. All reactions were carried out on a Peltier Thermal
Cycler (MJ Research, Waltham, Mass). PCR products separated on
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a 2% agarose gel. The PCR products were identified by being sub-
cloned with the TOPO TA Cloning kit (Invitrogen Corporation,
Carlsbad, Calif) and sequenced. Densitometric analysis was used
to quantify the PCR signal (1D Image Analysis Software; Eastman
Kodak Company, Rochester, NY).
Western Blot Analysis 
Homogenates from right lower lobe lung tissue of SCPA and control
specimens were obtained as described above. Equal aliquots of solu-
bilized protein were then separated by sodium dodecylsulfate–poly-
acrylamide gel electrophoresis (4%-12% gradient precast gel; Bio-
Rad Laboratories, Hercules, Calif). Proteins were transferred to a
polyvinylidene difluoride (PVDF) membrane (Amersham Corp,
Arlington Heights, Ill). The membrane was soaked in Tris-buffered
saline solution (10 mmol Tris-HCl, 250 mmol NaCl) containing 5%
nonfat powdered milk and 0.1% Tween 20 to block nonspecific bind-
ing. The membrane was then incubated overnight at 4°C with a 1:1000
dilution of an ACE monoclonal antibody (clone 9B9; Kamiya
Biomedical Company, Seattle, Wash). Blots were washed and incu-
bated for 30 minutes at 4°C with a peroxidase-conjugated anti-mouse
secondary antibody (1:10000 dilution; Amersham). Immunoreactivity
was visualized with the SuperSignal Chemiluminescent Substrate kit
(Pierce Chemical Company, Rockford, Ill). Quantitative assessment of
band densities was performed by scanning densitometry as above.
ACE Activity 
Segments of right lower lobe lung tissue of equal weights (0.25 g)
were placed in 1 mL of HEPES buffer, 0.05 mol/L, and homoge-
nized with a Tissuemizer T-25 homogenizer (Tekmar-Dohrmann,
Mason, Ohio). Homogenates were centrifuged at 1000g for 10 min-
utes and the supernatants at 30,000g for 30 minutes. The resulting
pellet was resuspended in 500 µL 0.05 mol/L HEPES buffer, pH 8.0,
in 0.1 mol/L NaCl, and 0.6 mol/L Na2SO4. The homogenate was
then diluted 1:20 for assay. ACE activity was determined as previ-
ously described by Ryan and associates.5 In brief, ACE activity was
measured by the generation of 3H-hippuric acid from the cleavage of
hippurlyglycyglyine, an ACE substrate. Homogenates were incubat-
ed with 16 mmol/L (0.125 mCi/mmol) 3H-labeled hippurlyglycyg-
lyine for 1 hour at 37°C. The reaction was terminated with 1 mL of
0.1 mmol/L HCl. Then, 1 mL of ethyl acetate was added to extract
the radiolabeled fragment cleaved by ACE. Samples were cen-
trifuged at 2000g for 20 minutes to separate the organic and aqueous
phases. Next, 0.5 mL of the upper organic layer was placed in a scin-
tillation vial, and counts per minute were measured on a scintillation
counter. All reactions were performed in duplicate. ACE activity was
normalized for protein content determined in each homogenate with
a Bio-Rad protein assay kit (Bio-Rad Laboratories).
AT-II Determinations 
Blood samples were drawn from the right pulmonary vein in Glenn
and control animals when they were put to death (1-15 weeks).
Samples were centrifuged at 4000g at 4°C for 20 minutes. Plasma
was removed and stored at –80°C for future analysis. Concentration
and purification of AT-II was accomplished by elution over Sep-Pak
C18 columns (Waters Corporation, Milford, Mass). AT-II levels
were determined by enzyme-linked immunosorbent assay with a
commercially available kit (Peninsula Labs, Belmont, Calif).
Statistical Analysis 
Data were analyzed with StatView software, a commercially avail-
able software package (SAS Institute, Inc, Cary, NC). The 4 time
points (1, 2, 5, and 15 weeks) were evaluated with 3 animals each in
Figure 1. The SCPA (classic Glenn shunt) as performed in this
model. SVC, Superior vena cava; IVC, inferior vena cava; RPA,
right pulmonary artery; LPA, left pulmonary artery; RA, right atri-
um; RV, right ventricle.
Figure 2. Reverse transcription PCR of ACE mRNA expression in
right lower lobe lung tissue after SCPA and sham operations.
Densitometric analysis of signal intensity for representative
mRNA samples is displayed for comparison.
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the experimental and sham controls for a total of 12 in each cohort.
Analysis of statistical differences between groups at each time point
was performed by unpaired, 2-tailed Student t tests. Significant dif-
ferences between SCPA and control groups were confirmed by
analysis of variance. Significance was established at the 95% confi-
dence level. All values are expressed as mean ± standard deviation.
Results
Detection of Pulmonary AV Shunting
Contrast echocardiography detected AV shunting in all ani-
mals evaluated 56 days or later (n = 23) after SCPA. No
shunting was detected in any animals studied up to 190 days
after sham surgery (n = 17). Atrial or ventricular septal
defects were not present in any of the animals.
ACE Messenger RNA Expression
ACE mRNA expression was significantly reduced after con-
struction of the Glenn shunt. Reverse transcription PCR
demonstrated a marked decrease in ACE mRNA in lung
homogenates up to 5 weeks after surgery. Densitometry
revealed a 72% ± 7.2% reduction in mRNA signal at 1 week
(P = .01), 62% ± 4.7% at 2 weeks (P = .01), and a 58% ±
3.2% decline at 5 weeks after surgery (Figure 2). At 15
weeks, the mRNA signal was reduced only 14% ± 5.2%
with a confidence interval < 95% (P = .06).
ACE Protein Expression
Cavopulmonary anastomosis caused a similar reduction in
ACE protein expression. Densitometric analysis of the
Western blots revealed that ACE protein expression was
reduced 93% ± 1.0% at 1 week (P < .001), 95.3% ± 1.3% at
2 weeks (P < .001), and 58.8% ± 3% at 5 weeks (P < .001)
after SCPA (Figure 3). There was no statistically significant
difference in protein expression between the experimental
and sham groups at 15 weeks after surgery (P = .76).
ACE Activity
A substantial early reduction in pulmonary ACE activity
was also observed after cavopulmonary anastomosis. This
reduction, however, progressively diminished as a factor of
time after surgery (Figure 4). One week after SCPA, ACE
activity was reduced 7-fold (P = .003). At 2 weeks, the
degree of reduction was 4.2-fold (P < .001) when compared
with the sham-operated animals. As time progressed after
surgery, this reduction was attenuated. At 5 weeks, pul-
monary ACE activity in SCPA animals was diminished 2.2-
fold (P = .006). At 15 weeks, there was no statistically sig-
nificant difference in ACE activity between the 2 groups (P
= .20) (Table 1).
AT-II Levels
The levels of AT-II present in the right pulmonary vein of the
SCPA lambs correlated with the initial, drastic decrease in
ACE activity and expression. Although levels of AT-II in
control lambs were constant over time, AT-II was reduced
73% ± 1% at 1 week (P < .001), 78% ± 4% at 2 weeks (P =
.005), and 59% ± 3.5% at 5 weeks after SCPA (P = .007)
(Figure 5). After 15 weeks, no significant differences exist-
ed between the 2 groups (P = .19).
Discussion
The development of pulmonary AV malformations after
cavopulmonary anastomosis is a well-documented but poor-
ly understood phenomenon. We have demonstrated a signif-
icant impairment of the pulmonary angiotensin system after
SCPA in the lamb. In our model, AV shunting is detectable
Figure 3. Western blot of ACE protein expression in right lower
lobe lung homogenates. Tissue was analyzed 1, 2, 5, and 15 weeks
after surgery. Shown below are the corresponding relative inten-
sities obtained from scanning densitometry of representative
Western blot samples.
Figure 4. Changes in ACE activity of lung homogenates at 1, 2, 5,
and 15 weeks after SCPA or sham operation.
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by bubble contrast echocardiography by 6 to 8 weeks after
SCPA. It is therefore important to recognize that the most
significant reduction in ACE expression, activity, and circu-
lating AT-II occurs before AV malformations are detectable,
a period of active pulmonary vascular remodeling.
Chronic pulmonary vasodilation is a hallmark of these
abnormal AV structures. A recent histologic analysis of pul-
monary AV malformations in children after cavopulmonary
anastomosis revealed lakes of dilated vessels, as well as
thin-walled vessels branching from precapillary arterioles.6
Other authors have described the appearance of abnormal
dilated vascular structures within the pulmonary interstitium
after SCPA.7,8 These vascular changes undoubtedly con-
tribute to the intrapulmonary shunting responsible for
cyanosis. Interruption in the normal function of ACE may
contribute significantly to the chronic dilatation of the
affected vasculature.
Furthermore, loss of pulmonary ACE expression and func-
tion reflects altered endothelial phenotype. ACE is concen-
trated on the pulmonary microvascular endothelium and
serves as an indicator of endothelial integrity. It is known that
ACE mRNA expression in endothelial cells is regulated in an
inverse relationship to their proliferative state.9 Down-
regulation of ACE may indicate dedifferentiation of the pul-
monary endothelium as a result of accelerated proliferation in
this setting of surgically induced vascular remodeling.
Various forms of endothelial injury such as shear stress and
oxidative damage have also been shown to suppress endothe-
lial ACE activity and expression.10,11 The altered physiology
after SCPA may be responsible for a similar insult to the
endothelium, impairing its ability to express ACE.
Development of AV malformations represents patholog-
ic pulmonary vascular remodeling in response to surgically
altered pulmonary blood flow. SCPA creates several rele-
vant modifications to the right pulmonary circulation. First,
there is a reduction in the blood volume in the right pul-
monary circulation. In sheep, blood return from the superi-
or vena cava is approximately one-third less than that from
the inferior vena cava. Moreover, blood flow to the right
lung is no longer pulsatile, because it bypasses the right side
of the heart. It is unlikely that nonpulsatile flow contributes
to the development of AV malformations, evidenced by the
low incidence of AV malformations after the Fontan opera-
tion.2 Another series demonstrated pulmonary AV shunting
after modified Fontan repairs only when hepatic venous
drainage was excluded.12
Exclusion of inferior vena caval blood from the right
lung is likely the most significant factor in the development
of AV malformations after the classic Glenn shunt. It has
been postulated that exclusion of hepatic venous effluent
interrupts the delivery of a mediator of normal vascular
development from the pulmonary circulation. Theoretically,
this “hepatic factor” would prevent pathologic vascular
remodeling. This assertion is supported by reports of AV
malformations resolving after inclusion of hepatic venous
blood.13,14 As yet, no such entity has been identified.
Further studies will be necessary to demonstrate whether the
absence of inferior vena caval blood flow is responsible for
the inhibition of ACE activity and expression after cavopul-
monary anastomosis.
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Discussion
Dr Guo-Wei He (Hong Kong, China). I have 2 questions. First,
why did you choose ACE? So many things are related to pul-
monary circulation and endothelial function, such as vasoconstric-
tors like endothelin-1 and vasodilators like nitric oxide and
epoprostenol (prostacyclin). 
Second, have you tried to measure nitric oxide release, which
probably is a more important indicator for endothelial function
after cavopulmonary shunt? 
Dr Malhotra. Thank you for those 2 important questions. First,
with regard to studying the other constrictors and regulators of vas-
cular tone in the pulmonary system, we actually began by examin-
ing levels of various vasoconstrictors and dilators in the pulmonary
venous system after the Glenn anastomosis. The only one that we
found that was significantly altered was AT-II. That led us to ask
whether we should be investigating ACE expression and activity. 
Second, we have looked at nitric oxide release. It is interesting
because we have demonstrated increased endothelial nitric oxide
synthase expression, without a corresponding increase in nitric
oxide production, suggesting that endothelial dysfunction may
occur in this setting.
Dr He. What about epoprostenol (prostacyclin)? 
Dr Malhotra. We have not yet evaluated that. 
Dr Edward D. Verrier (Seattle, Wash). I have a little difficul-
ty with the concept that vasodilatation alone has a potential to
induce a proliferative process. These AV malformations appear to
be an angiogenic type, proliferative process. Do you have any evi-
dence that simply lowering pulmonary vascular resistance actually
induces proliferation? 
Dr Malhotra. I am sorry if my conclusions were unclear. I was
trying to illustrate that ACE downregulation and loss of ACE activity
may represent dedifferentiation of the endothelium as a result of pro-
liferation. I did not want to suggest that the 2 processes were related. 
Dr Verrier. I am not an expert on this topic, but I was under the
impression there was evidence that hepatic angiogenic inhibiting
factors were released. Because of the uniqueness of the Glenn
anastomosis, these inhibitory factors bypassed the lung with a loss
of angiogenic inhibition, thereby leading to angiogenic prolifera-
tion and AV malformations. Have you looked at the relationship
between that and the lung and the vasodilatory pathways? Is there
a relationship that can be correlated? 
Dr Malhotra. I believe the evidence is substantial that if hepat-
ic venous effluent is excluded from the pulmonary circulation,
there is a propensity for these AV malformations to form. We are
presently examining the effect of different exposure to inferior and
superior vena caval blood on endothelial cell phenotype. However,
whether AV malformations are induced by a hypoxic insult or by
the lack of a protective factor derived from the liver is debatable.
As yet, no such “hepatic factor” has been identified.
Dr Ludwig K. von Segesser (Lausanne, Switzerland). The
Glenn shunt is in general used for problems related to severe
cyanosis. Did you try to mimic some of these scenarios or can you
speculate on this? 
Dr Malhotra. No. We used healthy lambs and did not use that
variable. However, in our model all animals with the SCPA had
pulmonary AV malformations by 8 weeks after surgery, so I doubt
that cyanosis is relevant to the development of AV malformations. 
Dr Hikaru Matsuda. My question concerns the relationship
between hepatic blood and the development of AV malformations.
If pulmonary blood flow is not obtaining hepatic blood directly, AV
malformations are likely to develop. However, in a regular Fontan
or a regular Glenn operation, this malformation does not occur as
often as in the total cavopulmonary shunt operation, in which the
total venous flow, except hepatic venous flow, goes directly to the
pulmonary flow. 
You mentioned that it is very interesting to look for a possible
relationship of the hepatic blood flow in this model.
You probably have seen some patients in whom AV malforma-
tions developed after the total cavopulmonary shunt operation. Are
the histologic changes of such patients similar to those which you
have seen in this experimental model? 
My second question concerns etiology. Do you think this is just
the hemodynamic consequences or is some tumoral effect
involved? 
Dr Malhotra. We have not performed total cavopulmonary anas-
tomosis on these animals, so I cannot comment on your first question.
Regarding the second question, inhibition of ACE expression at
the mRNA level suggests that pulmonary vasodilation after
cavopulmonary anastomosis is related to altered cellular physiolo-
gy due to the exclusion of hepatic venous effluent.
